United States - English - NLM (National Library of Medicine)

atlantic biologicals corp. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate oral solution is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant patients. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2) ], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: morphine sulfate oral solution is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.5)]. there are no available data with morphine sulfate oral solution in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published

United States - English - NLM (National Library of Medicine)

tris pharma inc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg in 5 ml

United States - English - NLM (National Library of Medicine)

hospira, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate injection is indicated for the management of pain severe enough to require use of an opioid analgesic by patient controlled analgesia (pca), and for which alternative treatments are inadequate. limitations of use preservative-free morphine sulfate injection is for administration via a compatible hospira infusion device. morphine sulfate injection is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2) ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6) ] - concurrent use of monoamine oxidase inhibitors (maois) or use of maois within the last 14 days [see warnings and precautions (5.7)]. - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings and precautions (5.11) ] - hypersensitivity to morphine (e.g., anaphylaxis) [see adverse reactions (6) ] risk summary prolonged use of opioid analgesics during pregnancy can c

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate injection is indicated for the management of pain severe enough to require use of an opioid analgesic by patient controlled analgesia (pca), and for which alternative treatments are inadequate. limitations of use preservative-free morphine sulfate injection is for administration via a compatible hospira infusion device. morphine sulfate injection is contraindicated in patients with: - significant respiratory depression [ see warnings and precautions (5.2) ] significant respiratory depression [ see warnings and precautions (5.2) ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see warnings and precautions (5.6) ] acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see warnings and precautions (5.6) ] - concurren

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 100mg - modified release tablet - 100 mg - active: morphine sulfate pentahydrate 100mg excipient: hyetellose hypromellose magnesium stearate opadry grey oy-8238 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 10mg - modified release tablet - 10 mg - active: morphine sulfate pentahydrate 10mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry buff oy-3607 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 30mg - modified release tablet - 30 mg - active: morphine sulfate pentahydrate 30mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry violet 0y-6708 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 60mg - modified release tablet - 60 mg - active: morphine sulfate pentahydrate 60mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry orange oy-3533 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - morphine sulfate pentahydrate, quantity: 15 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - morphine sulfate pentahydrate, quantity: 2 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.